AbbVie Inc (ABBV) Stake Raised by Greenline Partners LLC

Greenline Partners LLC lifted its stake in shares of AbbVie Inc (NYSE:ABBV) by 3.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,005 shares of the company’s stock after purchasing an additional 1,245 shares during the period. Greenline Partners LLC’s holdings in AbbVie were worth $3,868,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Morgan Stanley raised its position in shares of AbbVie by 3.2% during the second quarter. Morgan Stanley now owns 11,134,470 shares of the company’s stock worth $1,031,608,000 after purchasing an additional 348,882 shares during the period. Janus Henderson Group PLC raised its position in shares of AbbVie by 15.9% during the second quarter. Janus Henderson Group PLC now owns 5,243,956 shares of the company’s stock worth $485,867,000 after purchasing an additional 717,452 shares during the period. Bank of Montreal Can raised its position in shares of AbbVie by 9.2% during the third quarter. Bank of Montreal Can now owns 5,210,247 shares of the company’s stock worth $492,786,000 after purchasing an additional 438,201 shares during the period. Dimensional Fund Advisors LP raised its position in shares of AbbVie by 3.4% during the second quarter. Dimensional Fund Advisors LP now owns 4,824,617 shares of the company’s stock worth $447,001,000 after purchasing an additional 157,594 shares during the period. Finally, Aristotle Capital Management LLC raised its position in shares of AbbVie by 0.9% during the first quarter. Aristotle Capital Management LLC now owns 3,787,873 shares of the company’s stock worth $358,522,000 after purchasing an additional 34,727 shares during the period. 69.47% of the stock is currently owned by institutional investors.

Shares of ABBV stock opened at $90.14 on Friday. AbbVie Inc has a 1-year low of $77.50 and a 1-year high of $125.86. The company has a current ratio of 1.20, a quick ratio of 1.08 and a debt-to-equity ratio of 8.70. The firm has a market cap of $134.91 billion, a PE ratio of 16.10, a price-to-earnings-growth ratio of 0.83 and a beta of 1.62.



AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.13. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The business had revenue of $8.24 billion for the quarter, compared to the consensus estimate of $8.23 billion. During the same quarter in the previous year, the company posted $1.41 earnings per share. AbbVie’s revenue for the quarter was up 17.7% compared to the same quarter last year. On average, equities research analysts anticipate that AbbVie Inc will post 7.93 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be paid a $1.07 dividend. The ex-dividend date is Monday, January 14th. This represents a $4.28 dividend on an annualized basis and a yield of 4.75%. This is an increase from AbbVie’s previous quarterly dividend of $0.96. AbbVie’s payout ratio is 68.57%.

A number of equities research analysts have recently issued reports on ABBV shares. Credit Suisse Group set a $85.00 target price on AbbVie and gave the stock a “sell” rating in a research report on Saturday, October 20th. SunTrust Banks lowered their price target on AbbVie from $157.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, October 22nd. Wolfe Research initiated coverage on AbbVie in a report on Tuesday, October 23rd. They set an “underperform” rating on the stock. Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $105.00 price target on the stock in a report on Monday, October 1st. Finally, Bank of America lowered their price target on AbbVie from $107.00 to $106.00 and set a “buy” rating on the stock in a report on Thursday, October 4th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $103.68.

WARNING: This news story was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://dakotafinancialnews.com/2018/11/16/abbvie-inc-abbv-stake-raised-by-greenline-partners-llc.html.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.

See Also: What is insider trading?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply